Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574. 

Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.

The prevailing theory about the Omicron variant is that it is going to rip through the population quickly and possibly burn out, marking the downside of the COVID-19 pandemic. But researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark, just as the first Omicron wave subsided.

Johnson & Johnson announced that the company’s Imbokodo Phase IIb trial in HIV failed to hit the primary endpoint. The study evaluated J&J’s investigational HIV vaccine regimen in young women in sub-Saharan Africa at high risk of acquiring HIV.

University of Oxford researchers started clinical trials for a new vaccine that can potentially target a wide range of human immunodeficiency virus (HIV) variants. 

A Covid-19 vaccine being developed by CSL Ltd. and the University of Queensland was scrapped after numerous vaccine recipients reported receiving false positives on certain HIV tests, according to the Wall Street Journal.

The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.

The National Institutes of Health (NIH) ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.

Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.